GeneDx Holdings Corp.
WGS
$85.74
-$5.87-6.41%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 326.81M | 302.16M | 263.18M | 237.71M | 214.91M |
| Total Other Revenue | 3.33M | 3.29M | 4.05M | 5.95M | 6.94M |
| Total Revenue | 330.14M | 305.45M | 267.23M | 243.66M | 221.85M |
| Cost of Revenue | 114.68M | 111.00M | 108.23M | 108.20M | 110.57M |
| Gross Profit | 215.47M | 194.45M | 159.00M | 135.46M | 111.28M |
| SG&A Expenses | 178.85M | 167.91M | 163.40M | 163.09M | 173.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 2.43M | 2.43M | 2.34M | 3.34M | 3.19M |
| Total Operating Expenses | 342.54M | 326.91M | 317.17M | 320.45M | 339.68M |
| Operating Income | -12.40M | -21.46M | -49.94M | -76.80M | -117.83M |
| Income Before Tax | -38.39M | -52.63M | -84.23M | -118.33M | -135.88M |
| Income Tax Expenses | 186.00K | -343.00K | -730.00K | -855.00K | -861.00K |
| Earnings from Continuing Operations | -38.58 | -52.29 | -83.50 | -117.47 | -135.02 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.58M | -52.29M | -83.50M | -117.47M | -135.02M |
| EBIT | -12.40M | -21.46M | -49.94M | -76.80M | -117.83M |
| EBITDA | 9.08M | -408.00K | -23.65M | -47.77M | -83.68M |
| EPS Basic | -1.44 | -1.98 | -3.17 | -4.51 | -5.25 |
| Normalized Basic EPS | -0.57 | -0.92 | -1.79 | -2.40 | -2.94 |
| EPS Diluted | -1.44 | -1.98 | -3.17 | -4.51 | -5.25 |
| Normalized Diluted EPS | -0.57 | -0.92 | -1.79 | -2.40 | -2.94 |
| Average Basic Shares Outstanding | 109.65M | 107.56M | 105.69M | 104.38M | 103.19M |
| Average Diluted Shares Outstanding | 109.65M | 107.56M | 105.69M | 104.38M | 103.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |